Cargando…
Effects of teprotumumab on patients with long-standing, active thyroid eye disease
PURPOSE: Describe five cases of long-standing, active thyroid eye disease that responded to treatment with teprotumumab. OBSERVATIONS: Five patients with a greater than 9-month-history of thyroid eye disease, including two patients who had previously failed orbital radiotherapy, received eight doses...
Autores principales: | Vinson, Kyle B., Kirzhner, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987648/ https://www.ncbi.nlm.nih.gov/pubmed/35402750 http://dx.doi.org/10.1016/j.ajoc.2022.101348 |
Ejemplares similares
-
Teprotumumab in advanced reactivated thyroid eye disease
por: Cheng, Olivia T., et al.
Publicado: (2022) -
Early experience with teprotumumab for chronic thyroid eye disease
por: Ozzello, Daniel J., et al.
Publicado: (2020) -
Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease
por: Hoang, Thanh Duc, et al.
Publicado: (2021) -
A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease
por: Safo, Myra B., et al.
Publicado: (2021) -
Audiologic Demonstration of Ototoxicity From Teprotumumab Treatment in a Patient With Thyroid Eye Disease
por: Najjar, Wassim, et al.
Publicado: (2022)